Fatty-acid amide hydrolase (FAAH) catalyzes the intracellular hydrolysis of the endocannabinoid anandamide and other bioactive lipid amides. In the present study, we conducted a comparative characterization of the effects of the newly identified brain-impermeant FAAH inhibitor, URB937 ([3-(3-carbamoylphenyl)-4-hydroxy-phenyl] N-cyclohexylcarbamate), in various rodent models of acute and persistent pain. When administered by the oral route in mice, URB937 was highly active (median effective dose, ED50, to inhibit liver FAAH activity: 0.3 mg-kg−1) and had a bioavailability of 5.3%. The antinociceptive effects of oral URB937 were investigated in mouse models of acute inflammation (carrageenan), peripheral nerve injury (chronic sciatic nerve ligation) and arthritis (complete Freund’s adjuvant). In all models, URB937 was as effective or more effective than standard analgesic and anti-inflammatory drugs (indomethacin, gabapentin, dexamethasone) and reversed pain-related responses (mechanical hyperalgesia, thermal hyperalgesia, and mechanical allodynia) in a dose-dependent manner. ED50 values ranged from 0.2 to 10 mg-kg−1, depending on model and readout. Importantly, URB937 was significantly more effective than two global FAAH inhibitors, URB597 and PF-04457845, in the complete Freund’s adjuvant model. The effects of a combination of URB937 with the non-steroidal anti-inflammatory agent, indomethacin, were examined in the carrageenan and chronic sciatic nerve ligation models. Isobolographic analyses showed that the two compounds interacted synergistically to attenuate pain-related behaviors. Furthermore, URB937 reduced the number and severity of gastric lesions produced by indomethacin, while exerting no ulcerogenic effect when administered alone. The results indicate that the peripheral FAAH inhibitor URB937 is more effective than globally active FAAH inhibitors at inhibiting inflammatory pain. Our findings further suggest that FAAH and cyclooxygenase inhibitors interact functionally in peripheral tissues, to either enhance or hinder each other’s actions.
Chikungunya virus (CHIKV) is an Arbovirus that is transmitted to humans primarily by the mosquito species Aedes aegypti. Infection with this pathogen is often associated with fever, rash and arthralgia. Neither a vaccine nor an antiviral drug is available for the prevention or treatment of this disease. Albeit considered a tropical pathogen, adaptation of the virus to the mosquito species Aedes albopictus, which is also very common in temperate zones, has resulted in recent outbreaks in Europe and the US. In the present study, we report on the discovery of a novel series of compounds that inhibit CHIKV replication in the low μM range. In particular, we initially performed a virtual screening simulation of ∼5 million compounds on the CHIKV nsP2, the viral protease, after which we investigated and explored the Structure-Activity Relationships of the hit identified in silico. Overall, a series of 26 compounds, including the original hit, was evaluated in a virus-cell-based CPE reduction assay. The study of such selective inhibitors will contribute to a better understanding of the CHIKV replication cycle and may represents a first step towards the development of a clinical candidate drug for the treatment of this disease.
Demonstrating
intracellular protein target engagement is an essential step in the
development and progression of new chemical probes and potential small
molecule therapeutics. However, this can be particularly challenging
for poorly studied and noncatalytic proteins, as robust proximal biomarkers
are rarely known. To confirm that our recently discovered chemical
probe 1 (CCT251236) binds the putative transcription
factor regulator pirin in living cells, we developed a heterobifunctional
protein degradation probe. Focusing on linker design and physicochemical
properties, we generated a highly active probe 16 (CCT367766)
in only three iterations, validating our efficient strategy for degradation
probe design against nonvalidated protein targets.
The inhibition of NAD synthesis or salvage pathways has been proposed as a novel target for antitumoral drugs. Two molecules with this mechanism of action are at present undergoing clinical trials. In searching for similar novel molecules, we exploited copper-catalyzed [3 + 2] cycloaddition between azides and alkynes (click chemistry) to synthesize 185 novel analogues. The most promising compound displays an IC(50) for cytotoxicity in vitro of 3.8 +/- 0.3 nM and an IC(50) for NAD depletion of 3.0 +/- 0.4 nM. Herein, we strengthen previous data suggesting that this class of compounds induces autophagic cell death. In addition to characterizing this compound and providing a rationale via molecular docking, we reinforce the excellent potential of click chemistry for rapidly generating structure-activity relationships and for drug screening.
An investigation of Thapsia garganica afforded a series of tetracyclic C-19 dilactones, whose production was dependent on the time and location of the collection. These unusual tetrahomosesquiterpenoids are presumably biosynthesized via a carbon dioxide-triggered electrophilic polyolefin cyclization. Despite the structural differences with thapsigargin, these compounds showed SERCA-inhibiting properties.
The peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor
URB937 (3, cyclohexylcarbamic acid
3’-carbamoyl-6-hydroxybiphenyl-3-yl ester) is extruded from the brain and
spinal cord by the Abcg2 efflux transporter. Despite its inability to enter the
central nervous system (CNS), 3 exerts profound antinociceptive
effects in mice and rats, which result from the inhibition of FAAH in peripheral
tissues and the consequent enhancement of anandamide signaling at CB1
cannabinoid receptors localized on sensory nerve endings. In the present study,
we examined the structure-activity relationships (SAR) for the biphenyl region
of compound 3, focusing on the carbamoyl and hydroxyl groups in the
distal and proximal phenyl rings. Our SAR studies generated a new series of
peripherally restricted FAAH inhibitors and identified compound 35
(cyclohexylcarbamic acid 3’-carbamoyl-5-hydroxybiphenyl-3-yl ester) as
the most potent brain-impermeant FAAH inhibitor disclosed to date.
We propose a new QSRR model based on a Kernel-based partial least-squares method for predicting UPLC retention times in reversed phase mode. The model was built using a combination of classical (physicochemical and topological) and nonclassical (fingerprints) molecular descriptors of 1383 compounds, encompassing different chemical classes and structures and their accurately measured retention time values. Following a random splitting of the data set into a training and a test set, we tested the ability of the model to predict the retention time of all the compounds. The best predicted/experimental R value was higher than 0.86, while the best Q value we observed was close to 0.84. A comparison of our model with traditional and simpler MLR and PLS regression models shows that KPLS better performs in term of correlation (R), prediction (Q), and support to MetID peak assignment. The KPLS model succeeded in two real-life MetID tasks by correctly predicting elution order of Phase I metabolites, including isomeric monohydroxylated compounds. We also show in this paper that the model's predictive power can be extended to different gradient profiles, by simple mathematical extrapolation using a known equation, thus offering very broad flexibility. Moreover, the current study includes a deep investigation of different types of chemical descriptors used to build the structure-retention relationship.
A series of imidazo[1,2-
b
]pyridazin-8-amine kinase inhibitors were
discovered to allosterically inhibit the endoribonuclease function
of the dual kinase-endoribonuclease inositol-requiring enzyme 1α
(IRE1α), a key component of the unfolded protein response in
mammalian cells and a potential drug target in multiple human diseases.
Inhibitor optimization gave compounds with high kinome selectivity
that prevented endoplasmic reticulum stress-induced IRE1α oligomerization
and phosphorylation, and inhibited endoribonuclease activity in human
cells. X-ray crystallography showed the inhibitors to bind to a previously
unreported and unusually disordered conformation of the IRE1α
kinase domain that would be incompatible with back-to-back dimerization
of the IRE1α protein and activation of the endoribonuclease
function. These findings increase the repertoire of known IRE1α
protein conformations and can guide the discovery of highly selective
ligands for the IRE1α kinase site that allosterically inhibit
the endoribonuclease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.